Evoke Pharma (NASDAQ:EVOK) Downgraded by ValuEngine to “Sell”

Share on StockTwits

ValuEngine downgraded shares of Evoke Pharma (NASDAQ:EVOK) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning, ValuEngine reports.

Other equities analysts also recently issued research reports about the company. HC Wainwright downgraded Hydrogenics from a buy rating to a neutral rating in a research note on Friday, June 28th. Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a buy rating to a hold rating in a research note on Tuesday, May 7th.

Shares of NASDAQ EVOK opened at $0.88 on Tuesday. Evoke Pharma has a twelve month low of $0.50 and a twelve month high of $3.40. The business has a 50 day simple moving average of $0.66. The stock has a market cap of $20.47 million, a P/E ratio of -1.91 and a beta of 1.62.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). As a group, research analysts anticipate that Evoke Pharma will post -0.41 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Evoke Pharma in the first quarter valued at approximately $118,000. BlackRock Inc. lifted its stake in Evoke Pharma by 5.5% in the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after purchasing an additional 4,392 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Evoke Pharma in the first quarter valued at approximately $139,000. Institutional investors and hedge funds own 7.40% of the company’s stock.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

See Also: Exchange-Traded Funds (ETFs)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.